Esmeralda Woestenenk

The Drug Discovery & Development platform (DDD) works together with principal investigators (PIs) primarily at Swedish universities to generate prototype drugs based on their proposed therapeutic concept. We offer industry-standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept. We work with small molecules, human antibodies, oligonoucleotides and new modality therapeutics for polypharmacology and cell therapeutics.

Projects at the DDD platform commonly run for 4-5 years, during which we work closely together with the PI team with the aim to generate molecules that are ready for further development into drugs.